Illumina Inc. | Income Statement

Fiscal year is January-December. All values USD Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
1,421
1,861
2,220
2,398
2,752
3,333
Cost of Goods Sold (COGS) incl. D&A
450
550
643
711
882
1,006
Gross Income
971
1,311
1,577
1,688
1,870
2,327
SG&A Expense
644
801
926
1,083
1,216
1,417
EBIT
311
486
623
583
628
883
Unusual Expense
177
3
14
4
22
21
Non Operating Income/Expense
60
3
11
1
455
3
Interest Expense
40
42
42
33
37
57
Pretax Income
159
449
583
561
1,043
894
Income Tax
34
95
126
133
365
112
Consolidated Net Income
125
353
457
420
677
782
Net Income
125
353
462
454
725
826
Net Income After Extraordinaries
125
353
462
454
725
826
Net Income Available to Common
125
353
462
454
725
826
EPS (Basic)
0.90
2.37
3.10
3.07
4.90
5.54
Basic Shares Outstanding
125
136
145
147
146
147
EPS (Diluted)
0.90
2.37
3.10
3.07
4.90
5.54
Diluted Shares Outstanding
140
149
149
148
148
149
EBITDA
409
599
750
724
784
1,062
Other Operating Expense
16
24
28
21
26
27
Non-Operating Interest Income
5
4
5
10
19
44
Minority Interest Expense
-
-
4
35
48
44
Equity in Affiliates (Pretax)
-
-
-
1
-
-
Other After Tax Income (Expense)
-
-
-
9
1
-

About Illumina

View Profile
Address
5200 Illumina Way
San Diego California 92122
United States
Employees -
Website http://www.illumina.com
Updated 07/08/2019
Illumina, Inc. engages in the development and manufacture of integrated systems for the analysis of genetic variation and function. It operates through the Core Illumina and Consolidated Variable Interest Entity segments (VIE). The Core Illumina segment serve customers in the research, clinical and applied markets, and enable the adoption of a genomic solutions.